TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21505147
Drug: Metreleptin (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metreleptin (initial dose: 0.08 mg·kg(‐1)·day(‐1) for 3 mo, increased to 0.12 mg·kg(‐1)·day(‐1) if menstruation did not occur)
Study: 9333110
Drug: Paroxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (20 mg/day orally for 10 days)
Study: 9333110
Drug: Perphenazine (0.11
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perphenazine (0.11 mg/kg orally) after paroxetine pretreatment
Study: 8471404
Drug: Simvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (20 mg day‐1)
Study: 8471404
Drug: Pravastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (40 mg day‐1)
Study: 18190629
Drug: Variable dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Variable dosage of sildenafil (25, 50, 100 mg) or vardenafil (5, 10, 20 mg) determined by NPTR
Study: 18190629
Drug: Fixed low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fixed low-dose sildenafil 25 mg or vardenafil 5 mg
Study: 18190629
Drug: Variable dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Variable dosage of sildenafil or vardenafil
Study: 18190629
Drug: Fixed low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fixed low-dose sildenafil or vardenafil
Study: 7659137
Drug: Flutrimazole 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutrimazole 1% dermal cream
Study: 7659137
Drug: Clotrimazole 1%
Normalized name: CLOTRIMAZOLE 1% LOTION
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clotrimazole 1% dermal cream
Study: 26888731
Drug: Allogeneic-adipose-derived mesenchymal
Normalized name: Allogenic bone marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic-adipose-derived mesenchymal stem cells (ALLO-ASCs) injected into the anal sphincter (doses: 3 × 10(7), 6 × 10(7), 9 × 10(7) cells)
Study: 26888731
Drug: 0.9% normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% normal saline injection mixed with fibrin glue (placebo)
Study: 25075802
Drug: Cognitive Behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavior Therapy (CBT) delivered by a child anxiety specialist in the primary care clinic
Study: 7615189
Drug: Mesalamine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalamine (1.5 g twice a day)
Study: 823950
Drug: Thyrotropin releasing
Normalized name: Thyrotropin releasing factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyrotropin releasing hormone (TRH)
Study: 23815739
Drug: SMART Arm
Normalized name: benzalkonium chloride Topical Foam [Smart San]
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMART Arm training with OT-stim and usual therapy
Study: 23815739
Drug: SMART Arm
Normalized name: benzalkonium chloride Topical Foam [Smart San]
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMART Arm training without OT-stim and usual therapy
Study: 11757182
Drug: Radiotherapy doses
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy doses of 26-34 Gy
Study: 11757182
Drug: Radiotherapy doses
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy doses of 36 Gy
Study: 11757182
Drug: Radiotherapy doses
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy doses of 40 Gy or more
Study: 25794092
Drug: Simethicone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simethicone (200 mg)
Study: 21147298
Drug: Low concentration
Normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low concentration (LC) contrast medium (150 mg iodine/ml)
Study: 21147298
Drug: High concentration
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High concentration (HC) contrast medium (300 mg iodine/ml)
Study: 18942560
Drug: Audiovisual support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Audiovisual support in adjunct to written informative form
Study: 8839907
Drug: Carboplatin/5-fluorouracil concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin/5-fluorouracil concurrent with radiotherapy (group I)
Study: 6370157
Drug: Prophylactic administration
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic administration of 4 units of platelet concentrates at the end of bypass
Study: 6370157
Drug: Prophylactic administration
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic administration of platelet concentrates
Study: 31481568
Drug: Systematic medication
Normalized name: Integrase Inhibitors, antiinfectives for systematic use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systematic medication review intervention using the 'Systematic Tool to Reduce Inappropriate Prescribing'‐Assistant (STRIPA)
Study: 31481568
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care sham intervention (GP discusses medication list completeness)
Study: 31481568
Drug: Systematic medication
Normalized name: Integrase Inhibitors, antiinfectives for systematic use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systematic medication review intervention
Study: 29489977
Drug: G‐CSF injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF injection for 3 days after chemotherapy
Study: 26458034
Drug: Generic glatiramer
Normalized name: Glatiramer
DrugBank: Glatiramer (DB05259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic glatiramer acetate (20 mg)
Study: 26458034
Drug: Brand glatiramer
Normalized name: Glatiramer
DrugBank: Glatiramer (DB05259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brand glatiramer acetate (20 mg)
Study: 15161434
Drug: Gemcitabine (Gemzar®)
Normalized name: gemcitabine Injection [Gemzar]
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine (Gemzar®) as a single agent
Study: 15161434
Drug: Gemcitabine in
Normalized name: gemcitabine Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine in combination with platinum-based chemotherapy
Study: 18084949
Drug: Gemcitabine in
Normalized name: gemcitabine Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine in combination with radiotherapy
Study: 12075638
Drug: IV ephedrine
Normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV ephedrine infusion (5 mg.min(‐1) immediately after spinal injection)
Study: 12075638
Drug: Bolus administration
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus administration of IV ephedrine (10 mg in case of hypotension)
Study: 10458204
Drug: Docetaxel at
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel at 100 mg/m2 administered as a 1-hour intravenous infusion every 3 weeks
Study: 10458204
Drug: Docetaxel at
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel at 100 mg/m2 or 75 mg/m2
Study: 2180328
Drug: Antidepressants or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants or placebo (3-6 weeks treatment)
Study: 6345340
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal (10 g)
Study: 22959457
Drug: Intramuscular progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular progesterone (IMP) 25-50 mg/d
Study: 22959457
Drug: 8% Crinone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8% Crinone vaginal gel
Study: 20492837
Drug: OROS-MPH (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: OROS-MPH (titrated to 72 mg/d)
Study: 18541000
Drug: Apixaban 5
Normalized name: apixaban 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban 5 mg twice-daily
Study: 18541000
Drug: Apixaban 10
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Apixaban 10 mg twice-daily
Study: 18541000
Drug: Apixaban 20
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Apixaban 20 mg once-daily
Study: 11220454
Drug: Electrophysiologic testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrophysiologic testing (EP)‐guided therapy with implantable defibrillator
Study: 8994421
Drug: Direct NO
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct NO donors (infusion of linsidomine followed by oral molsidomine)
Study: 1587069
Drug: Oral diltiazem
Normalized name: diltiazem Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diltiazem
Study: 30396627
Drug: Cinnamon (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnamon (1000 mg capsules)
Study: 30396627
Drug: Placebo (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1000 mg starch capsules)
Study: 22196836
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy intervention (brief, nurse-delivered during hospitalization with a 1-week booster phone call)
Study: 12608624
Drug: Inhaled anesthetics
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled anesthetics and/or radiation exposure
Study: 9649457
Drug: Omeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (40 mg AM and 20 mg PM) for 7 days
Study: 7978090
Drug: Fenfluramine (60‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenfluramine (60‐mg oral dose)
Study: 3263508
Drug: Continuous-infusion IL-2
Normalized name: IL-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous-infusion IL-2 at 3 X 10(6) U/m2 per day
Study: 30063644
Drug: Nebivolol 5
Normalized name: nebivolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol 5 mg (single dose)
Study: 30063644
Drug: Irbesartan 150
Normalized name: irbesartan 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan 150 mg (single dose)
Study: 30063644
Drug: Nebivolol (weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol (weekly administration)
Study: 30063644
Drug: Irbesartan (weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan (weekly administration)
Study: 22801017
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal medicine (Tsang‐Erh‐San extract granules and Houttuynia extract powder)
Study: 955230
Drug: Full-strength dimethylsulfoxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-strength dimethylsulfoxide (DMSO) and potent topical corticosteroids
Study: 31217178
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) diclofenac (75 mg)
Study: 31217178
Drug: Oral (PO)
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral (PO) diclofenac (100 mg)
Study: 26685923
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CG) (n=21), received no treatment.
Study: 23377231
Drug: Bilateral movement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral movement therapy
Study: 23377231
Drug: Unilateral movement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unilateral movement therapy
Study: 19656689
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 2.5% w/w Reseda luteola extract (s-RE)
Study: 17403977
Drug: Low doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low doses of olanzapine
Study: 17403977
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of olanzapine
Study: 17403977
Drug: Low doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low doses of risperidone
Study: 17403977
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of risperidone
Study: 31059991
Drug: Control (standard-of-care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard-of-care pharmacotherapy alone)
Study: 23328710
Drug: Cinacalcet with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinacalcet with low-dose active vitamin D
Study: 19486273
Drug: Melatonin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin treatment (daily use in 65% of children, occasional use in 12%)
Study: 19486273
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of melatonin treatment
Study: 11842864
Drug: Chondroitin sulfate
Normalized name: Chondroitin Sulfate
DrugBank: Chondroitin sulfate (DB09301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chondroitin sulfate (1200 mg) and glucosamine hydrochloride (1500 mg) daily for 12 weeks
Study: 31062834
Drug: Vortioxetine, 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine, 15 mg/day (n=36)
Study: 31062834
Drug: Other common
Normalized name: Common carp
DrugBank: Common carp (DB10614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other common antidepressants (n=72)
Study: 31062834
Drug: Other common
Normalized name: Common carp
DrugBank: Common carp (DB10614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other common antidepressants
Study: 21560476
Drug: Direct intramyocardial
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct intramyocardial injection of autologous bone marrow cells (CD34+ selected cells)
Study: 21560476
Drug: Direct intramyocardial
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct intramyocardial injection of autologous bone marrow cells (all mononuclear cells)
Study: 21560476
Drug: Direct intramyocardial
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct intramyocardial injection of autologous bone marrow cells (both CD34+ selected cells and all mononuclear cells)
Study: 19702080
Drug: Lixu Jieyu
Normalized name: Lixudebart
DrugBank: Lixudebart (DB19244)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lixu Jieyu Recipe (LJR), 100 mL twice a day for 3 months
Study: 19702080
Drug: Vitamin B
Normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B tablets (10 mg twice a day), adenosine triphosphate (ATP, 20 mg thrice a day), and Oryzanol tablets (20 mg thrice a day)
Study: 12919762
Drug: Intranasal mupirocin
Normalized name: Mupirocin
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal mupirocin combined with octenidine dihydrochloride bodywash over a period of five days
Study: 8202722
Drug: rHuEPO treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuEPO treatment in responding patients
Study: 8202722
Drug: rHuEPO therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuEPO therapy overall
Study: 28608311
Drug: Allopurinol 600
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Allopurinol 600 mg administered 24 hours before and immediately before the procedure
Study: 28608311
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered 24 hours before and immediately before the procedure
Study: 21258075
Drug: Levosimendan (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan (12 µg bolus followed by an infusion of 0.2 µg kg(‐1) min(‐1))
Study: 16799350
Drug: TIVA (Total
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIVA (Total Intravenous Anesthesia with Propofol)
Study: 10887047
Drug: Activated Charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated Charcoal (7.5 g)
Study: 10887047
Drug: Activated Charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated Charcoal (15 g)
Study: 10887047
Drug: Diethylcarbamazine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diethylcarbamazine (150 mg)
Study: 8397726
Drug: Gamma-hydroxybutyric acid
Normalized name: gamma-Hydroxybutyric acid
DrugBank: gamma-Hydroxybutyric acid (DB01440)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gamma-hydroxybutyric acid (GHB) 25 mg/kg orally
Study: 8397726
Drug: GHB treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHB treatment suspended after 8 days
Study: 23829056
Drug: Permethrin 2.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Permethrin 2.5% cream (two applications with one week interval)
Study: 17283867
Drug: Eccentric dosing
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eccentric dosing of nitrates
Study: 17283867
Drug: Continuous dosing
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous dosing of nitrates
Study: 1684481
Drug: Topical cyclosporin
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cyclosporin A formulations
Study: 28402756
Drug: Instrumented manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instrumented manual therapy plus self‐stretching
Study: 26311526
Drug: Reduced dose
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced dose radiotherapy
Study: 26311526
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose post-operative radiotherapy
Study: 17305763
Drug: Esomeprazole 10
Normalized name: esomeprazole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 10 mg once daily for 4 weeks
Study: 11158034
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of recombinant human GHRH-(1-44)-amide
Study: 9143859
Drug: Non-users of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-users of antimalarials
Study: 2960473
Drug: Enoximone (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone (150 mg tid for 6 weeks)
Study: 31389201
Drug: Trelagliptin 25
Normalized name: Trelagliptin
DrugBank: Trelagliptin (DB15323)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Trelagliptin 25 mg
Study: 29401258
Drug: Orthonasal delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orthonasal delivery of linalool (12%) at 6 L/min
Study: 29401258
Drug: Orthonasal delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orthonasal delivery of vanillin (25%) at 6 L/min
Study: 29401258
Drug: Retronasal delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retronasal delivery of linalool (12%) at 8 L/min
Study: 29401258
Drug: Retronasal delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retronasal delivery of vanillin (25%) at 8 L/min
Study: 18256431
Drug: Mass drug
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mass drug administration (MDA) for lymphatic filariasis, administered annually for four years.
Study: 16109592
Drug: Naltrexone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (50 mg/day) for 14 weeks
Study: 12520627
Drug: Reduced-dose probenecid
Normalized name: Probenecid
DrugBank: Probenecid (DB01032)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced-dose probenecid (RDP) 2 g at 1 hour before cidofovir
Study: 12520627
Drug: Standard-dose probenecid
Normalized name: Probenecid
DrugBank: Probenecid (DB01032)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard-dose probenecid (SDP) 2 g at 3 hours before cidofovir, then 1 g at 2 and 8 hours after cidofovir
Study: 12520627
Drug: Cidofovir 5
Normalized name: Cidofovir
DrugBank: Cidofovir (DB00369)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cidofovir 5 mg/kg as a 1-hour infusion after saline prehydration
Study: 10799813
Drug: Paracetamol tablet
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paracetamol tablet with sodium bicarbonate (630 mg)
Study: 10799813
Drug: Paracetamol tablet
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paracetamol tablet with sodium bicarbonate (400 mg)
Study: 10799813
Drug: Paracetamol tablet
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paracetamol tablet with calcium carbonate (375 mg)
Study: 10799813
Drug: Conventional paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional paracetamol tablet (500 mg)
Study: 10799813
Drug: Soluble paracetamol
Normalized name: Disprol Soluble Paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble paracetamol tablet
Study: 8780277
Drug: Spinal anesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anesthesia with 12.5 mg bupivacaine plus saline (SS)
Study: 1610577
Drug: Midazolam 2
Normalized name: midazolam 2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 2 mg IV
Study: 1610577
Drug: Placebo (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline 2 ml IV)
Study: 6386936
Drug: Intranasal fenoterol
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal fenoterol (0.2 mg in each nostril, total 0.8 mg)
Study: 6386936
Drug: Oral fenoterol
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fenoterol (0.4 mg inhalation)
Study: 6386936
Drug: Intranasal fenoterol
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal fenoterol
Study: 31837238
Drug: Ordinal outcomes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ordinal outcomes based on baseline platelet count (cutoff, 150 × 10^9/L)
Study: 30026000
Drug: Niraparib (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niraparib (300 mg once daily)
Study: 28683357
Drug: Concurrent training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent training (16-week, 3 times per week of heart rate guided-aerobic plus resistance training)